(Q36118405)

12 August 2017

1 reference

title

Current chemotherapeutic strategies for rhabdomyosarcoma (English)

1 reference

12 August 2017

1 reference

1 reference

Michela Casanova

2

0 references

Andrea Ferrari

object named as

Andrea Ferrari

series ordinal

1

0 references

publication date

1 April 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

283-294

1 reference

Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Soft tissue sarcomas of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

The Intergroup Rhabdomyosarcoma Study-I. A final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

The Intergroup Rhabdomyosarcoma Study-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Ifosfamide in Pediatric Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: Report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from intergroup rhabdomyosarcoma study iv.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

The development of VAC chemotherapy in Rhabdomyosarcoma: What does one do for an encore?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Ifosfamide nephrotoxicity in pediatric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

High-dose chemotherapy for rhabdomyosarcoma: where do we go from here

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

High-dose therapy with autologous stem cell rescue for pediatric sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Vinca alkaloids: anti-vascular effects in a murine tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

European collaboration in trials of new agents for children with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.283

21 January 2018

Identifiers

DOI

10.1586/14737140.5.2.283

1 reference

12 August 2017

1 reference